Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease.

Immunogenetics - 1 Jul 2013

Pawlak-Adamska Edyta, Daroszewski Jacek, Bolanowski Marek, Oficjalska Jolanta, Janusz Przemyslaw, Szalinski Marek, Frydecka Irena

Abstract excerpt

Orbital fibroblast differentiation to adipocytes is a peroxisome proliferator-activated receptor g (PPARg)-dependent process essential for pathogenic tissue remodeling in Graves' orbitopathy (GO). PPARg2 Pro¹²Ala polymorphism modulates expression and/or function of the molecule encoded by this gene and is a promising locus of GO. Here, we analyzed associations of PPARg2 Pro¹²Ala with clinical manifestation of GO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipocytes
Share to Comorbidity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graves Ophthalmopathy

Share to PPAR gamma

Share to Sex Factors

Share to Smoking

Share to Thyroid Diseases

Source

Identifiers

PMID: 23604462
DOI: 10.1007/s00251-013-0702-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease.PMID 23604462Read ↗

The Pro 12 Ala PPAR gamma gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO).Semantic proximity Read ↗

Unravelling the pathogenic mechanisms in Graves’ orbitopathySemantic proximity Read ↗

Role of genetics and epigenetics in Graves' orbitopathy.Semantic proximity Read ↗

Association between polymorphisms in the TSHR gene and Graves' orbitopathy.Semantic proximity Read ↗

Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.Semantic proximity Read ↗

Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves’ OphthalmopathySemantic proximity Read ↗

Risk factors for development or deterioration of Graves' ophthalmopathy.Semantic proximity Read ↗

Significance of HLA in the development of Graves’ orbitopathySemantic proximity Read ↗

Genotype-phenotype correlations in Graves' disease.Semantic proximity Read ↗

MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves’ orbitopathySemantic proximity Read ↗

Association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and susceptibility to Graves' ophthalmopathy.Semantic proximity Read ↗

Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.